Comparison of Three-Year Clinical Outcome of Sirolimus- and Paclitaxel-Eluting Stents Versus Bare Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction (from the RESEARCH and T-SEARCH Registries)

Daemen, Joost; Tanimoto, Shuzou; García‐García, Héctor M.; Kukreja, Neville; Sande, Meike van de; Sianos, Georgios; Jaegere, Peter P.T. de; Domburg, Ron T. van; Serruys, Patrick W.

doi:10.1016/j.amjcard.2006.11.070

Cited by 131 publications

(85 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Survival status was obtained from municipal civil registries. Reinfarction was diagnosed by recurrent symptoms and/or new electrocardiographic changes in association with increases in creatine kinase and creatine kinase myoglobin levels of >3 times the upper normal limit 27 . A combined endpoint was used due to the small number of events and the fact that combined outcomes are commonly used in cardiovascular outcome studies.…”

Section: Study Endpointmentioning

confidence: 99%

Brief Depression Screening with the PHQ-2 Associated with Prognosis Following Percutaneous Coronary Intervention with Paclitaxel-Eluting Stenting

et al. 2009

Self Cite

View full text Add to dashboard Cite

Section: Study Endpointmentioning

confidence: 99%

Brief Depression Screening with the PHQ-2 Associated with Prognosis Following Percutaneous Coronary Intervention with Paclitaxel-Eluting Stenting

et al. 2009

Self Cite

View full text Add to dashboard Cite

“…No significant difference was observed between BMS and DES in terms of the incidence of death and recurrent AMI [1,2,6,[10][11][12]. On the other hand, accumulating data began to show a higher risk of stent thrombosis in those treated with DES over a 1-year follow-up period [3,6,9].…”

Section: Discussionmentioning

confidence: 99%

Incidence and Clinical Predictors of Stent Restenosis and Early Stent Occlusion in Patients with Acute Myocardial Infarction Treated by Bare Metal Stents: Importance of Infarct Location and Serum Creatinine Level

Uemori¹,

Sugitani²,

Tamada³

et al. 2014

Angiol

View full text Add to dashboard Cite

GroupsAmong these 242 patients, 226 underwent either ischemia-driven or planned follow-up coronary angiography within 8 months. Thus, *Corresponding author: Manabu Shirotani, Cardiology Department, Nara Hospital, Kinki University Faculty of Medicine, 1248-1, Otoda-Cho, Ikoma, Nara, 630-0293, Japan, Tel: +81 743 77 0880; Fax: +81 743 77 0901; E-mail: manabu@nara.med.kindai.ac.jp AbstractBackground: Bare Metal Stents (BMS) have been commonly used for recanalization of an infarct-related artery in Japanese patients with Acute Myocardial Infarction (AMI). We sought to examine predictors of binary restenosis and early Stent Occlusion (SO) in these patients. Methods:Among 242 consecutive patients with AMI treated by BMS implantation as reperfusion therapy, 226 underwent either ischemia-driven or follow-up coronary angiography within 8 months. Restenosis change in the stented segment was found in 56. Among them, 10 patients had early SO on an angiogram. Multivariate analysis was performed to obtain predictors of restenosis and early SO.Results: Predictors for restenosis were Left Anterior Descending Artery (LAD) involvement (odds ratio (OR) 2.32, p=0.024), serum creatinine (SCr) on admission (OR 1.29 per 0.1mg/dl increase, p=0.001), and stent size (OR 0.43 per 0.5mm increase, p=0.001). Those for early SO were left main trunk or LAD involvement (OR 27.0, p=0.029), SCr (OR 1.65 per 0.1mg/dl increase, p=0.005) and leukocyte count (OR 1.28 per 1,000/microliter increase, p=0.037) on admission. SCr was significantly higher in patients with early SO than in those with restenosis (median 1.05, Interquartile Range (IQR) 0.80-1.10 vs. median 0.80, IQR 0.70-1.00, p=0.035). Conclusion:In patients with AMI treated with BMS, both restenosis and early SO were increased by anterior wall involvement and elevation of SCr level. Higher SCr may be subject to more occlusive changes. It is suggested that in early SO, an inflammatory mechanism may be involved.

show abstract

“…In 3 previous randomized studies, angiographic restenosis was significantly lower with SES compared with PES, [18][19][20] and there are several possible reasons for this difference: (1) differences in the pharmacological action of sirolimus and paclitaxel, (2) drug-release kinetics, (3) the pattern of drug distribution in the arterial wall, and (4) stent characteristics. 21 Many investigators have suggested that several factors influence the higher risk of restenosis after DES implantation. A previous study showed that predictive factors of restenosis after PCI with SES or PES in patients presenting with symptomatic coronary artery disease were vessel size, final diameter stenosis, and DES type (PES).…”

Section: Circulation Journal Vol73 December 2009mentioning

confidence: 99%

Lack of Clinical Benefit of Improved Angiographic Results With Sirolimus-Eluting Stents Compared With Paclitaxel and Zotarolimus-Eluting Stents in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Choi

Rha

Chen

et al. 2009

Circ J

View full text Add to dashboard Cite

rug-eluting stents (DESs) have been rapidly accepted in real world clinical practice by the interventional community, largely being used in percutaneous coronary interventions (PCI). 1 Previous randomized trials have reported that the first generation DESs, including sirolimus-eluting stents (SES; Cypher™) and paclitaxel-eluting stents (PES; Taxus™) reduced the incidence of restenosis and the need for revascularization over 6-12 months' follow-up compared with bare metal stents (BMSs). 2,3 Recent trials of DESs in acute myocardial infarction (AMI) have reported that DESs are superior to BMSs in reducing the need for repeat revascularization. [4][5][6][7] However, DES implantation in the AMI setting is still known to be an important off-label indication and safety concerns regarding stent thrombosis (ST) and associated major adverse cardiac events (MACE) have been raised because of the systemic thrombotic milieu of the early period of AMI and the combined potentially increased thrombogenicity of the DES itself by causing delayed healing of the coronary endothelium compared with BMSs. [8][9][10] However, recently the KAMIR (Korea AMI Registry) study group reported that the use of DESs in Korean patients with AMI was clinically safe and effective. 11 There is very limited information regarding the angiographic and clinical outcomes among the different DESs in patients with AMI undergoing PCI, especially DESs other than SES and PES. Park et al showed that SES implantation in AMI patients was associated with a reduction of angiographic restenosis at 6 months compared with PES. 12 However, to our knowledge, there are few ongoing studies and no published data comparing SES, PES, and zotarolimus-eluting stents (ZES; Endeavor™) in AMI patients undergoing PCI, so this study was designed to investigate whether there are differences in safety and efficacy, specifically the 6-month angiographic and 1-year clinical outcomes, in patients with AMI undergoing PCI with these 3 different major early-generation DESs.

show abstract

Comparison of Three-Year Clinical Outcome of Sirolimus- and Paclitaxel-Eluting Stents Versus Bare Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction (from the RESEARCH and T-SEARCH Registries)

Cited by 131 publications

References 26 publications

Brief Depression Screening with the PHQ-2 Associated with Prognosis Following Percutaneous Coronary Intervention with Paclitaxel-Eluting Stenting

Brief Depression Screening with the PHQ-2 Associated with Prognosis Following Percutaneous Coronary Intervention with Paclitaxel-Eluting Stenting

Incidence and Clinical Predictors of Stent Restenosis and Early Stent Occlusion in Patients with Acute Myocardial Infarction Treated by Bare Metal Stents: Importance of Infarct Location and Serum Creatinine Level

Lack of Clinical Benefit of Improved Angiographic Results With Sirolimus-Eluting Stents Compared With Paclitaxel and Zotarolimus-Eluting Stents in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Contact Info

Product

Resources

About